NICE appraises Iressa

The U.K.'s NICE issued a preliminary appraisal for Iressa gefitinib from AstraZeneca plc (LSE:AZN; NYSE:AZN) to treat locally advanced or metastatic non-small cell lung cancer (NSCLC). The committee requested more information on the clinical and cost effectiveness of Iressa, including additional analyses of the Phase III IPASS trial. ...